Canada's economy is about 3.5% or 4% of the G7 plus the European Union, so you're a small but important part of that. If Canada chooses to not do a pull incentive and the rest of the G7 does, the innovation solution will probably be achieved, but the drugs will not be available in Canada. For a relatively small amount of money, done collectively with other G7 partners, there could be a great solution.
One other thing I'd like to say, Mr. Holman, is that we have to remember that this saves a lot of money. If we don't address AMR, every surgery becomes more dangerous and more risky—every caesarean section, every hip or knee replacement, every cancer treatment. The number two cause of death with cancer is infection, not cancer. This is an investment in saving money going forward. I understand that the budget issues are difficult, but this is an area in which prevention is really remarkably cost-effective.